Simple exploration of 148231-12-3

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.148231-12-3, you can also check out more blogs about148231-12-3

In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 148231-12-3, name is 5,8-Dibromoquinoxaline, introducing its new discovery. 148231-12-3

NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE

The present invention relates to compounds of formula (I), ab (I), wherein R1 to R3 and L are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.148231-12-3, you can also check out more blogs about148231-12-3

Reference£º
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2011 | ChemSpider